Q3 EPS Forecast for Maze Therapeutics Raised by Analyst

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Maze Therapeutics from ($1.06) to ($0.71), maintaining a "Buy" rating with a $34.00 price target.
• As of August 12, the company's stock price was reported at $13.35, down by 1.8%, with a 1-year price range between $6.71 and $19.19.
• Five analysts have issued a buy rating for Maze Therapeutics, resulting in an average rating of "Buy" and a consensus price target of $25.60.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 earnings estimates for shares of Maze Therapeutics in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst A. Ghosh now forecasts that the company will earn ($0.71) per share for the quarter, up from their previous forecast of ($1.06). HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. HC Wainwright also issued estimates for Maze Therapeutics' Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($2.73) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($1.16) EPS.

A number of other analysts have also weighed in on MAZE. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Wedbush assumed coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company. Based on data from MarketBeat, Maze Therapeutics has an average rating of "Buy" and a consensus target price of $25.60.

Maze Therapeutics Stock Performance

Shares of MAZE stock traded up $0.15 during trading hours on Friday, hitting $13.60. 197,120 shares of the company's stock were exchanged, compared to its average volume of 200,083. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $19.19. The stock has a 50 day simple moving average of $13.95.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its holdings in Maze Therapeutics by 452.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after purchasing an additional 438,274 shares in the last quarter. Engineers Gate Manager LP purchased a new position in Maze Therapeutics during the second quarter valued at approximately $125,000. Bank of America Corp DE lifted its holdings in Maze Therapeutics by 33.6% during the second quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock valued at $71,000 after purchasing an additional 1,455 shares in the last quarter. Finally, CW Advisors LLC purchased a new position in Maze Therapeutics during the second quarter valued at approximately $371,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.